METHODS FOR KYNURENINE SYSTEM IN HUNTINGTON'S DISEASE

227-43分量初始多参数数据库的分析 在144个大脑样本中显示出显著的尿酸分泌差异， 亨廷顿病之间的5-羟色胺能和多巴胺能系统 并控制壳核。这些都与喹啉酸一致。 神经元变性假说。在第二阶段研究中，我们的目标是 创建一个更大的数据库，其中包含大约4000个样本 组织和不同疾病之间使用的方法 多参数测量和快速数据简化的程序， 欧空局神经化学分析仪的移交与管理 (NCA)。将对几种不同HD和对照的组织进行分析 脑区检查运动神经异常是否为原发性 或继发于胶质细胞增多症，并在血浆和脑脊液中确定它们是否 缺陷的一般表述。类似的组织将在 其他障碍(阿尔茨海默病；S和帕金森)S病、肌萎缩侧索硬化症、精神分裂症 以确定这些异常是否是HD独有的，并排除药物 相关的异常。测试HD模型的测量将在 急、慢性兴奋性毒素损伤及喂养动物模型的建立 有门腔分流和没有门腔分流的型号。这项工作的长期目标 是提供HD的数据库和生化模型，可用作 制定治疗策略的指南。

The analysis of an initial multiparameter data base of 227-43 components in 144 brain samples indicated significant differences in the kynurenic, serotonergic and dopaminergic systems between Huntington's Disease (HD) and control putamen. These were consistent with the quinolinic acid hypothesis of neuronal degeneration. In the Phase II study, we purpose to create a larger data base of approximately 4000 samples from additional tissues and among different disorders using the methods for multiparameter measurements and the procedures for rapid data reduction, transfer and management developed for the ESA Neurochemical Analyzer (NCA). Tissues will be analyzed from several different HD and control brain regions to examine whether the kynurenic abnormalities are primary or secondary to gliosis, and in plasma and CSF to determine if they are general expressions of a defect. Similar tissues will be examined among other disorders (Alzheimer;s and Parkinson"s disease, ALS, Schizophrenia) to determine if the abnormalities are unique to HD and to rule out drug related anomalies. Measurements to test the HD model will be made on animal models of acute and chronic excitotoxin lesions and in feeding models with and without portacaval shunts. The long term goal of the work is to provide a data base and biochemical model of HD that can be used as a guide to develop therapeutic strategies.